Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Cash & Equivalents (2017 - 2025)

Inmune Bio's Cash & Equivalents history spans 9 years, with the latest figure at $27.7 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 17.34% year-over-year to $27.7 million; the TTM value through Sep 2025 reached $27.7 million, down 17.34%, while the annual FY2024 figure was $20.9 million, 41.64% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $27.7 million at Inmune Bio, down from $33.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $84.5 million in Q3 2021 and bottomed at $19.3 million in Q1 2025.
  • The 5-year median for Cash & Equivalents is $39.5 million (2021), against an average of $44.7 million.
  • The largest annual shift saw Cash & Equivalents surged 720.6% in 2021 before it crashed 49.02% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $74.8 million in 2021, then crashed by 30.29% to $52.2 million in 2022, then tumbled by 31.26% to $35.8 million in 2023, then tumbled by 41.64% to $20.9 million in 2024, then skyrocketed by 32.56% to $27.7 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Cash & Equivalents are $27.7 million (Q3 2025), $33.4 million (Q2 2025), and $19.3 million (Q1 2025).